A recent study by Nagoya University researchers revealed that microRNAs in urine could be a promising biomarker to diagnose brain tumors. Their findings have indicated that regular urine tests could help early detection and treatment of brain tumors, possibly leading to improved patient survival.
For a new paper published in the journal Clinical Microbiology Reviews, a team of researchers led by Concordia engineers sifted through hundreds of papers on COVID-19 detection tools and technologies. They wanted to categorize and understand what exists, what is lacking and what can be improved. The result is a thorough assessment of the field citing almost 600 separate papers that cover an extensive body of literature.
The effects of COVID-19 on the brain can be accurately measured with positron emission tomography (PET), according to research presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Annual Meeting. The detailed depiction of areas of cognitive impairment, neurological symptoms and comparison of impairment over a six-month time frame has been selected as SNMMI's 2021 Image of the Year.
Researchers at the University of Maryland School of Medicine (UMSOM) have developed two rapid diagnostic tests for COVID-19 that are nearly as accurate as the gold-standard test currently used in laboratories. Unlike the gold standard test, which extracts RNA and uses it to amplify the DNA of the virus, these new tests can detect the presence of the virus in as little as five minutes using different methods.
A phase III clinical trial has validated the effectiveness of the prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL in detecting and localizing recurrent prostate cancer. Approved by the FDA last month, the radiotracer identified metastatic lesions with high positive predictive values regardless of anatomic region, adding to the evidence that PSMA-targeted radiotracers are the most sensitive and accurate agents for imaging prostate cancer. This study was presented at the SNMMI 2021 Annual Meeting.
A new positron emission tomography (PET) radiotracer can detect abdominal aortic aneurysms (AAAs) and potentially predict when they will rupture, according to research presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting. Targeting a novel biomarker associated with AAA, the radiotracer is effective both in diagnosis and in providing information to assist in the development of AAA treatments, of which there currently are none.
According to AJR, high-dose intranodal lymphangiography with ethiodized oil is a safe and effective procedure for treating high-output postsurgical chylothorax with chest tube removal in 83% of patients. Previously, no data were available on the safety or benefits of injecting higher doses of ethiodized oil to treat patients with refractory postoperative chylothorax. No early or late clinically relevant complications, including symptomatic pulmonary or paradoxical embolism, were recorded for any of the patients.
Diego Mastroeni of the NDRC teamed up Forest White and Douglas Lauffenburger, to explore how protein and signaling pathways change in patients with Alzheimer's disease. Their work creates a new model of disease progression, taking advantage of the heterogeneity that is inherent to human studies.
A new non-contact laser imaging system developed by engineering researchers at the University of Waterloo, is designed to detect telltale signs of major blinding diseases in retinal blood and tissue that typically go unseen until it is too late.
In patients with mild cognitive impairment, taking lipophilic statins more than doubles their risk of developing dementia compared to those who do not take statins. According to research presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting, positron emission tomography (PET) scans of lipophilic statin users revealed a highly significant decline in metabolism in the area of the brain that is first impacted by Alzheimer's disease.